Ab&B Bio-Tech Co. Ltd. JS

As of June 30, 2025, Ab&B Bio-Tech Co. Ltd. JS has 393.44M shares outstanding.

These figures are as of June 30, 2025. The EV/Sales ratio of 10.35 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2025, Ab&B Bio-Tech Co. Ltd. JS maintains a current ratio of 0.44, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2,722.95, indicating elevated leverage, while an interest coverage ratio of -5.74 demonstrates limited ability to service its debt obligations.

These figures are as of the close on April 28, 2026.

Over the twelve months ended June 30, 2025, Ab&B Bio-Tech Co. Ltd. JS posted a gross margin of 91.08, reflecting its pricing power and cost economics. The operating margin of -41.86 and net profit margin of -48.37 provide insight into operational efficiency.

As of June 30, 2025, Ab&B Bio-Tech Co. Ltd. JS has an Altman Z-Score of -1.99, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.